Results 41 to 50 of about 30,153 (204)

A non-synonymous coding change in the CYP19A1 gene Arg264Cys (rs700519) does not affect circulating estradiol, bone structure or fracture

, 2011
Background The biosynthesis of estrogens from androgens is catalyzed by aromatase P450 enzyme, coded by the CYP19A1 gene on chromosome 15q21.2. Genetic variation within the CYP19A1 gene sequence has been shown to alter the function of the enzyme.
Mullin, B., Ingley Evan, Lewis, J., Evan Ingley, Wilson Scott G, McNab, Tegan, Jenny Z Wang, Wang, J., Wang, J.Z., Deogan, M.S., Prince, R.L., McNab Tegan J, Ben H Mullin, Chew Shelby, McNab, T.J., Chew, S., Wang Jenny Z, Mandeep S Deogan, Richard L Prince, Mullin Ben H, Scott G Wilson, Tegan J McNab, Lewis, J.R., Prince, R., Ingley, E., Prince Richard L, Deogan Mandeep S, Deogan, M., Wilson, S., Wilson, S.G., Mullin, B.H., Lewis Joshua R, Shelby Chew, Joshua R Lewis   +33 more
core   +1 more source

Successful treatment of low-grade endometrial cancer in premenopausal women with an aromatase inhibitor after failure with oral or intrauterine progesterone

Gynecologic Oncology Reports, 2017
Introduction: Young women with endometrial intraepithelial hyperplasia or low-grade endometrial carcinoma are potential candidates for conservative fertility sparing therapy utilizing progesterone rather than hysterectomy.
Alli Straubhar, Andrew P. Soisson, Mark Dodson, Elise Simons   +3 more
doaj   +1 more source

Treatment with an aromatase inhibitor suppresses high-temperature feminization of genetic male (YY) Nile tilapia

, 2002
High temperature (36° C) treatment during sexual differentiation caused significant changes in sex ratio in YY male Nile tilapia Oreochromis niloticus fry (64.5% males compared to 100.0% males at 28° C), while dietary treatment with a chemical ...
Penman, David, Kwon, Joon Yeong, McAndrew, Brendan   +2 more
core   +1 more source

Apoptosis and autophagy in breast cancer cells following exemestane treatment. [PDF]

PLoS ONE, 2012
Aromatase inhibitors (AIs), which block the conversion of androgens to estrogens, are used for hormone-dependent breast cancer treatment. Exemestane, a steroidal that belongs to the third-generation of AIs, is a mechanism-based inhibitor that binds ...
Cristina Amaral, Margarida Borges, Soraia Melo, Elisiário Tavares da Silva, Georgina Correia-da-Silva, Natércia Teixeira   +5 more
doaj   +1 more source

A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer

Nature Communications, 2022
Neoadjuvant therapy is recommended for patients with locally advanced breast cancer. Here the authors report the results of a phase 2 clinical trial of oral neoadjuvant therapy with pyrotinib (pan-HER tyrosine kinase inhibitor), letrozole (aromatase ...
Nan Niu, Fang Qiu, Qianshi Xu, Guijin He, Xi Gu, Wenbin Guo, Dianlong Zhang, Zhigao Li, Yi Zhao, Yong Li, Ke Li, Hao Zhang, Peili Zhang, Yuanxi Huang, Gangling Zhang, Hongbin Han, Zhengang Cai, Pengfei Li, Hong Xu, Guanglei Chen, Jinqi Xue, Xiaofan Jiang, Alireza Hamidian Jahromi, Jinshi Li, Yu Zhao, Eduardo de Faria Castro Fleury, Shiwen Huo, Huajun Li, Guy Jerusalem, Domenico Tripodi, Tong Liu, Xinyu Zheng, Caigang Liu   +32 more
doaj   +1 more source

ICSI cycles in women over 40 years: analysis of 3 different ovarian stimulation protocols

Middle East Fertility Society Journal, 2018
Purpose: To compare the clinical and laboratory outcomes of GnRH agonist stop, aromatase inhibitor/flexible antagonist and ultrashort flare GnRHa/flexible GnRH antagonist protocols in women (40–44) years undergoing ICSI.
H. Sibai, E.A. Elgindy, M.I. Mostafa
doaj   +1 more source

Aromatase Inhibitors for Ovulation Induction [PDF]

The Journal of Clinical Endocrinology & Metabolism, 2015
Normogonadotropic anovulation, including polycystic ovary syndrome (PCOS), is one of the main causes of infertility. Recent meta-analysis and randomized controlled trial suggest the use of aromatase inhibitors (ie, letrozole) as effective drug and first-line treatment to restore fertility in these patients.
openaire   +3 more sources

Aromatase inhibitor–associated musculoskeletal pain: An overview of pathophysiology and treatment modalities

SAGE Open Medicine, 2022
Since their introduction into clinical use in the 1970s, aromatase inhibitors have been a cornerstone of therapy for estrogen-receptor positive breast cancer in postmenopausal women.
Nelly Grigorian, Steven J Baumrucker
doaj   +1 more source

Origin of aromatase inhibitory activity via proteochemometric modeling [PDF]

PeerJ, 2016
Aromatase, the rate-limiting enzyme that catalyzes the conversion of androgen to estrogen, plays an essential role in the development of estrogen-dependent breast cancer.
Saw Simeon, Ola Spjuth, Maris Lapins, Sunanta Nabu, Nuttapat Anuwongcharoen, Virapong Prachayasittikul, Jarl E.S. Wikberg, Chanin Nantasenamat   +7 more
doaj   +2 more sources

Table_2_Construction and validation of a risk prediction model for aromatase inhibitor-associated bone loss.docx

, 2023
PurposeTo establish a high-risk prediction model for aromatase inhibitor-associated bone loss (AIBL) in patients with hormone receptor-positive breast cancer.MethodsThe study included breast cancer patients who received aromatase inhibitor (AI) treatment.
Yue Zhou (71752), Meiling Chu (250816), Yue Zhou, Hongfeng Chen (713780), Yulian Yin, Binjun He (15364351), Meiling Chu, Tian Meng, Jingjing Wu (153040), Yulian Yin (15364348), Binjun He, Jingjing Wu, Lan Jin, Hongfeng Chen, Meina Ye (787067), Tian Meng (589922), Lan Jin (464006), Meina Ye   +17 more
core   +1 more source